Patricia Uber

[Dr.Khan @DrBilal_khan]

Excellent talk by @PalakShahMD at @ISHLT 2026 on Redefining the Usefulness of dd-cfDNA Measurements: Reading Between the Fragments.

#ISHLT2026 #transplant

[Dr.Khan @DrBilal_khan]

Take-home from the debate:

Non-invasive tools (cfDNA, etc.) are transforming care—but require guardrails.
Best use:

- Screening
- Trend monitoring

Worthy debate by Dr Marta Farrero Torres
(Team Con)!

#ISHLT2026 #Teamcon #DEBATES

[Dr.Khan @DrBilal_khan]

Routine non-invasive rejection surveillance for all heart transplant patients is:

-Safe
-Effective
-Guideline-supported
-Patient-centered

Biopsy is no longer the only answer.
By Dr Shelly Hall!

#ISHLT2026 #Debate #TeamPro #screening

[Dr.Khan @DrBilal_khan]

Medication adherence = the fifth vital sign.

At @ISHLT 2026, Sabina De Geest highlights that nonadherence post-transplant is common—and measurable.

From self-reports ➝ digital pills ➝ drug level monitoring, the future is objective, continuous, and data-driven.

Very interesting model!

#ISHLT2026 #translant #novelmodels

[Yevgeniy Brailovsky DO MSc FACC @YevgeniyBr]

We share updates on Definition, Diagnosis and Treatment Strategies for submassive and massive PE. Work led by @mh_b_choi @Y_Elfatatry @darki_amir @LoyolaMedPERT @jeff_pert @PERTConsortium https://t.co/MsimS1d8XF

[JACC Journals @JACCJournals]

SGLT2-inhibitors in anthracycline-cardiotoxicity prevention: a question of ketone bodies, myocardial energetics and mitochondria. https://t.co/PcnklQH1cF

#JACCCardioOnc #CardioOnc #SGLT2i #Anthracycline @Borjaibanez1 @Massimi78530343 @Daniellemedinah

[HFSA @HFSA]

Congratulations to Mandeep R. Mehra, MBBS, MSc, FRCP, winner of this year's HFSA Lifetime Achievement Award for his significant contributions to the field of #heartfailure. Learn more about Dr. Mehra here https://t.co/pOHThYwEAW #HFSA2024

[Aditi Nayak @AditiNayakMD]

Many congratulations to my incredible mentor @MRMehraMD on winning the lifetime achievement award from @HFSA this year! A richly deserved testament to his foundational impact on our practice of advanced HF, visionary leadership and mentorship. SO proud!🥹
https://t.co/OEXgQzLgLP

[Ahmed Bennis MD 🫀 @drbennisahmed]

Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review

Tachycardia, AF, and PVCs can result in cardiomyopathy or AiCM

Appropriate treatment of AiCM can reverse ventricular systolic dysfunction and potentially decrease morbidity and mortality.

https://t.co/rZD7BEoAFX

[Giuseppe Galati @GiuseppeGalati_]

#HeartTransplantation 🫀
🔍Focus on Donor recovery strategies , LVAD a new therapies
A great review from @marisa1109 @mrchrtfaildoc @LuPoten et al
From pre/post -Tx to new horizons
@DrNasrien @DrMarthaGulati @ShelleyZieroth @gbiondizoccai @JavedButler1
https://t.co/ioEg76YnPM

[Transplantation @TransplantJrnl]

The latest developments in left ventricular assist devices (LVADs) for patients with advanced heart failure are discussed in this excellent review. #hearttransplantation #TransplantTwitter# https://t.co/91RGln5oqV

[Circulation Research @CircRes]

@CircRes The Interface Between #Cardioimmunology, #Myocardial Health, and #Disease Compendium Alert!

Myocardial #Inflammation in #HeartFailure with Reduced & Preserved #EF
https://t.co/NEevBe6bsT

Authored by Drs. @PilarAlcaidePhD @kallikourdis @RamonaE_9 & @SDPrabhuMD

[Circulation @CircAHA]

treatment of hypertrophic cardiomyopathy: CYP2C19 is important in mavacamten pharmacokinetics. Treatment without genotyping risks reduced ejection fraction in poor metabolizers @KathrynMcGurk @drjamesware @ImperialNHLI @BHFCoREImperial @MRC_LMS https://t.co/Ja9Mw49ogi

[Circulation Research @CircRes]

@CircRes The Interface Between #Cardioimmunology, #Myocardial Health, and #Disease Compendium Alert!

The Emerging Field of Cardio-Immunology: Past, Present and Foreseeable Future https://t.co/HVa7e7Zkie

Authored by @DLMANN_MD

[Ivan Netuka @netuka_ivan]

Management of Apixaban HeartMate 3 BTT pts within the DOT-HM3 Study; online in JCF. Outcomes at discharge post-HTx positive; considerable morbidity, though. Judicious use in select patients may be considered while weighing all risks and benefits on an individual patient level.

[Henry Han @HanCardiomd]

Tipping the Scale Toward a More Accurate and Equitable Assessment of #HFrEF Pharmacotherapy Eligibility: A Call to Incorporate #Cystatin C in #eGFR

#CardioRenal @ESC_Journals @NMHheartdoc

https://t.co/zs6eLxvzWR @ShelleyZieroth @BiykemB @JavedButler1 @kidney_boy @denisfouque1

[Ivan Netuka @netuka_ivan]

We are pleased to inform that our DOT-HM3 Trial results in partnership between IKEM and The Brigham Harvard just got online! Our results suggest a safety signal of Apixaban use with the HM3 up to a 6-months time point in stable LVAD patients. https://t.co/98omoxGm2W

[Elizabeth Warren @ewarren]

For too long, research on women’s health has been underfunded, & women have felt the consequences—in missed diagnoses, inadequate treatments, & worse outcomes. I was very glad to join @DrBiden as she announced major new funding to help turn this around.
https://t.co/odNWLSkeKk

[Yevgeniy Brailovsky DO MSc FACC @YevgeniyBr]

Join us for a great discussion in challenging cases.Geared towards trainees! #Amyloidosis is a multi-system disease,let’s get a multidisciplinary representation! @TempleCards @TJHeartFellows @PennCVFellows @LankenauCV @CooperCVFellows @syaddana_neuro @andrewchap361 @JeffMedChiefs

[Cardiology Fellowship Training at Tufts MC @TuftsMCCVFellow]

More of our favorite attending presenting at medicine grand rounds! We ❤️ learning from @NutritionHF & @IRajapreyar